Home / Learn / Resource Detail

Implementation of a Bispecific T-Cell Engager Therapy Program at a Community Cancer Center— [MINI PODCAST] EP 156

June 25, 2024

Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!

Development of this comprehensive bispecific antibody program included policy development; toxicity management; creation of patient and staff education documents; creation of clinician tools like a toxicity scoring and charting tool and an electronic order set that segregates treatment options; and a monitoring system to safely transition patients from inpatient to outpatient care. 

 

 

 

Guest:

Courtney VanHouzen, PharmD 

PGY-2 Oncology Resident 

Munson Healthcare, Cowell Family Cancer Center 

Traverse City, Michigan  

 

“While this [implementation of bispecific T-cell engager therapy] is not an easy thing to make happen, it’s possible for it to be done safely and effectively. That’s what we’re trying to show community cancer centers across the country—that they’re able to offer this therapy to their patients.” 

 Hear more about this innovation at the ACCC 41st National Oncology Conference, October 9-11, 2024, in Minneapolis, Minnesota. 

Resources:

 


The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Community Cancer Centers.